Longcor Jarrod

COO Longcor Jarrod adds 8,680 shares at $2.88, expanding stake 74% while stock trades 78% below 52-week high in unprofitable biotech.

COO Longcor Jarrod purchased nearly 8,700 shares at a discount, increasing his position by approximately three-quarters—a substantial commitment at a price substantially below the stock's 52-week high. This is his third open-market purchase in the past 36 months, demonstrating a consistent pattern of buying rather than selling at this company. His prior two purchases at Cellectar showed mixed results: one delivered solid gains over the following quarter, while the other declined, indicating his timing at this company has been inconsistent even when buying at lower price levels. The company itself remains unprofitable with recent quarterly losses, making this purchase notable as buying into fundamental weakness rather than strength. The combination of a senior executive accumulating shares while the company faces losses and the stock trades deeply depressed suggests either confidence in a turnaround or exposure to meaningful downside if the operational challenges persist.

COO Jarrod Longcor bought 10,000 shares at $4.99 on 2025-07-02; stock down -94.7% from 52-week high of $90.60, up 361.3% holdings.

Longcor, the Chief Operating Officer, purchased 10,000 shares at $4.99, increasing his holdings by 361.3% from 2,768 to 12,768 shares. The timing is notable: his prior buy at CLRB on 2025-01-10 generated a 90d return of +2822.9%, indicating this insider has successfully timed prior accumulations at this ticker. However, the current backdrop is stark—the stock has collapsed -94.7% from its 52-week high of $90.60 and is down -42.4% over the trailing 30 days, coinciding with an unprofitable fiscal year (net income of $-6,604,029.00). A cluster pattern is present, with 2 other insiders also buying within the past 14 days. The combination of a demonstrated track record of well-timed buys at this ticker, significant personal capital deployment, and coordinated insider accumulation during a severe drawdown warrants investor scrutiny into management's confidence in recovery and any non-public information that may be driving the coordinated activity.

COO Longcor Jarrod purchased 30,000 shares of CLRB at $0.28 on 2025-01-10; stock now -92.2% from 52-week high.

Longcor Jarrod, Chief Operating Officer, purchased 30,000 shares at $0.28 per share, increasing his holdings by 56.5% from 53,141 to 83,141 shares. The transaction occurred at a price dramatically depressed relative to the 52-week high of $122.10, with the current price of $9.50 representing a -92.2% decline from that peak. The company reported net income of $-14.7M in its most recent full fiscal year, indicating sustained unprofitability. This acquisition by a senior executive during a period of severe equity drawdown and operational losses presents a factual data point requiring investor review of the company's operational trajectory and the executive's underlying rationale.